Abstract
HIV-1 patients place an economic burden on the health system. The objectives of this study were to estimate the direct HIV-1 costs and cost-related factors of HIV-1 patients in Israel and identify cost predictors. We conducted a retrospective study of randomly selected HIV-1 patients aged ≥18 who visited a large outpatient clinic in 2015 and/or 2019. Yearly costs of physician and nurse visits, antiretroviral therapy (ART) and laboratory tests were calculated in USD using the 2020 purchasing power parities. Associations between disease characteristics and costs were analyzed using univariate and multivariable analysis. The median (IQR) total direct costs per patient per year were USD 12,387 (9813–14,124) and USD 12,835 (11,651–13,970) in 2015 (n = 284) and 2019 (n = 290), respectively. ART accounted for approximately 77% of all direct costs, followed by laboratory tests (20%) and medical visits (3%) in both studied years. Being female (USD +710), first yearly viral load <50 c/mL (+$1984) and ≥20 years with HIV-1 (USD +1056) were independently associated with higher costs. In conclusion, HIV-1 cost was stable in the studied period. Viral load and time since diagnosis were the major determinants associated with HIV-1 costs. ART and laboratory tests accounted for 97% of the costs. Therefore, these factors should be considered when planning future expenditures.
Subject
Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health
Reference35 articles.
1. Available online: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, 2022.
2. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety;Scarsi;Drugs,2020
3. HIV care cost in England: A cross-sectional analysis of antiretroviral treatment and the impact of generic introduction;Ong;HIV Med.,2019
4. The economic burden of late entry into medical care for patients with HIV infection;Fleishman;Med. Care,2010
5. Economic burden of late presentation in HIV disease in Austria: A comparison of the initial costs imposed by advanced HIV disease vs. non-late presentation;Grabmeier-Pfistershammer;Wien. Klin. Wochenschr.,2013